Released on: April 18, 2008, 4:48 pm

Press Release Author: raniah/GTCbio

Industry: Biotech

Press Release Summary: Dr. George Wang, Senior Scientist of Pharmacokinetics and
Drug Metabolism at Amgen will speak at GTCbio's 3rd Assay Development & Screening
Technologies Conference on June 5-6, 2008 in San Francisco, CA. Dr. Wang will
present on screening anti-idiotype antibody pairs for the quantification of
monoclonal antibody therapeutics in serum.

Press Release Body: MONROVIA, CA - Dr. George Wang, Senior Scientist of
Pharmacokinetics and Drug Metabolism at Amgen will speak at GTCbio's 3rd Assay
Development & Screening Technologies Conference on June 5-6, 2008 in San Francisco,
CA. Dr. Wang will present on screening anti-idiotype antibody pairs for the
quantification of monoclonal antibody therapeutics in serum.

Representing a significant share of the biopharmaceutical market, efficacy and
safety of monoclonal antibodies therapeutics (drug); that provide specific cures to
disease can be evaluated by needing to determine its concentration in biological
matrix (e.g., serum) with specific, sensitive and robust bioanalytical method. Using
anti-idiotype antibodies (anti-ids) against the drug to form a sandwich ELISA will
help to achieve that goal. Here Dr. Wang and his group present a case study on how
to screen the anti-ids as critical reagents for drug development support. In brief,
multiple clones of anti-drug antibody were labeled with biotin and HRP. Then they
were paired up and tested in an ELISA format with drug as the analyte. Good anti-id
pairs were selected based on signal strength, signal/noise ratio, antibody titer,
etc. After that, the drug target, the matrix, and Fab fragment of the drug were
employed to assess other properties of the anti-id pairs. Best pair was selected by
weighting data from all these screening tests. The final pair selected showed high
affinity to the drug. When used for drug quantification in serum, the assay was
validated to be accurate, precise, specific and robust. The anti-ids screening
approach as demonstrated here could be widely used for the preclinical and clinical
support of other antibody-based therapeutics.

GTCbio\'s 3rd Assay Development and Screening Technologies conference will provide
attendees with critical information to utilize in the discovery and development of
assays, while keeping them informed about the latest screening technologies for both
high-throughput screening and high-content screening. Topics being covered include
cell based assays, high throughput screening, high content screening, in vitro
assays and screening, novel assay and screening technologies, and target validation.



Web Site: http://gtcbio.com/Index.aspx

Contact Details: 434 W. Foothill Blvd.
Monrovia, CA 91016
Tel. 626 256 6405
Fax 626 256 6460